---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-082608"
form_type: "8-K"
ticker: "COCH"
cik: "0001840877"
company_name: "Envoy Medical, Inc."
filed_at: "2025-08-29T23:59:59+00:00"
generated_at: "2026-05-17T09:18:01.690757+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Envoy Medical faces Nasdaq delisting for failing MVLS requirement

## Summary
- Nasdaq notified Envoy Medical on August 26, 2025 that it failed to regain compliance with the $35M MVLS requirement within a 180-day cure period.
- Company requested a hearing on August 29, 2025, which stays trading suspension until the Panel issues a decision.
- Envoy cites recent debt extinguishment as a pathway to regain compliance but offers no assurance of continued listing.
- Trading would have been suspended September 4, 2025 without the hearing request.

## SEC filing metadata
- accession: 0001213900-25-082608
- form_type: 8-K
- ticker: COCH
- cik: 0001840877
- company_name: Envoy Medical, Inc.
- filed_at: 2025-08-29T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840877/000121390025082608/0001213900-25-082608-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840877/000121390025082608/ea0255235-8k_envoy.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-082608
- JSON: https://secwatch.observer/filing/0001213900-25-082608.json
- Plain text: https://secwatch.observer/filing/0001213900-25-082608.txt

## Key facts
- Listing & Compliance Notices
  Envoy Medical, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).
  - Exchange: nasdaq
  - Notice: delisting notice
  - Deficiency: market value
  - Rules: 5550(b)(2)
  source text: August 26, 2025, the Company received a determination letter from Nasdaq notifying the Company that it has not regained compliance with the MVLS Requirement within the 180 day cure period. The determination letter informed the Company that it can request a hearing regarding Nasdaq’s determination with a Hearings Panel (the “Panel”) by September 2, 2025 to discuss how the Company believes it will regain compliance and why the Company believes the Hearing Panel should grant an extension. If the Company did not make a request to the Hearings Panel, the trading of the Company’s securities would be
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840877/000121390025082608/0001213900-25-082608-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.